Ready to consult, design, conduct and submit preclinical studies you need for your product. We are flexible, effective and affordable.
– advanced tox studies supporting phase I – III CT
– expertise in non-rodent (HNP, dogs, pigs, cats, rabbits, ferrets) and rodent tox
– BEQ/BA/PK/TK
– human & veterinary products (small molecules, vaccines, biotech derived, medical device
food/feed),
– revision of study documentation, implementation GLP
– GLP certified 1991
– CIR certified

Our mission is to participate and assist in the development of scientific projects by offering a comprehensive range of techniques and skills to execute the best pathology services. We have experience in preparing and evaluating histologic slides from all sort of tissues and species used in non-clinical research and development. Our objective is to build effective, constructive and trusted, long-term partnerships with our customers.

At the time of a new industrial revolution, we are convinced that if factories must become smart and connected, the men and women remain the beating heart of production activities. To achieve this transformation for all and by all, it is necessary to rethink human-machine-data interactions.

By leveraging intuitive 3D digital twin technologies, we empower biopharmaceutical teams to easily access data and optimize processes from planning and simulation, to operator learning and asset management.

Founded in 2018, Palm’Data is focusing on lifesciences industry (pharmaceutical, cosmetics, medical devices). Our solutions enable us to support our clients with the organization, protection and use of their data, whatever the medium (paper, electronic, samples, biological specimens) in compliance with GxP regulations. Quality is our DNA, and our clients are our number one priority.

At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. To learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.

Real Research is a dynamically grown biotechnological start-up founded in 2017 by two enthusiastic founders. To obtain reliable data, Real Research has developed a unique 3D cell culture hydrogel called LifeGel. LifeGel is a technology platform which can be customised to mimic the physiological environment of cancer and various organs. Real Research is collaborating with pharma companies and provides necessary services and knowledge to clients.

The French association for animal health industry (SIMV) represents manufacturers and marketers (on the French market) of medicines and reagents for pets and for farm animals. In order to contribute to the competitiveness of its member companies, the SIMV defines its value creation through its trades:

Federating ;

Anticipating;

Advising/training/informing;

Being watchful;

Representing the positions of its members.

We are commercializing a treatment for a severe form of corneal blindness called limbal stem cell deficiency. This rare disease causes a significant societal burden because it occurs especially in young and working age people. The treatment is based on IP-protected technology for differentiating highly potent limbal stem cells from human pluripotent stem cells, providing an unlimited source of therapeutic cells. Our technology is currently in the preclinical phase.